Helus Pharma receives a speculative Buy rating due to its lead drug HLP003, an oral treatment for major depressive disorder showing promising Phase 2 results and FDA Breakthrough Therapy status. The company’s current valuation undervalues HLP003’s potential, which could reach an implied enterprise value of $1.5 billion if Phase 3 trials succeed in late 2026. Risks include trial challenges and market launch hurdles, but sufficient cash and upcoming catalysts could boost the stock significantly.
A New York legal case, Noah Doe, claims ownership of 39,069 dormant Bitcoin addresses valued at $293 billion under abandoned property laws. This challenges the core principle of Bitcoin self-custody, which relies on private keys, not inactivity, to p...
BlackRock's USD Institutional Digital Liquidity Fund (BUIDL) on Avalanche surged past $900 million in assets, doubling from about $464 million in just one week. This rapid growth reflects increasing institutional demand for tokenized U.S. Treasury as...
RE Protocol has introduced on-chain reinsurance tokens that allow insurance risk to be funded, priced, and settled using blockchain technology. This innovation aims to provide insurers with faster access to capital and more transparent risk pricing c...
Bitcoin Improvement Proposal 110 (BIP-110), a soft fork aimed at restricting arbitrary data like Ordinals on the Bitcoin network, is under scrutiny. Blockstream CEO Adam Back argues that misconceptions about Bitcoin's architecture are driving the deb...
Bitcoin traded mostly sideways last week, fluctuating around $61,800 to $64,000 as investors reacted to the US Federal Reserve's June meeting minutes showing divided views on interest rates. Renewed US-Iran conflict pushed oil prices and Treasury yie...
